Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin E

This article was originally published in The Tan Sheet

Executive Summary

Short-term supplementation at varying doses is safe and free of significant adverse events in healthy adults 65 and older, Simin Nikbin Meydani, Tufts University, et al., report in the August American Journal of Clinical Nutrition. In a randomized, double-blind, placebo-controlled study of 88 healthy older adults, the researchers examined the effects on general health of 60, 200 and 800 IU vitamin E (all-rac-alpha-tocopheral) administered daily for four months. Meydani et al. conclude supplemental vitamin E up to 800 mg per day "does not have an adverse effect on hepatic or renal function, intermediary metabolism, hematologic status, plasma lipid and lipoprotein concentrations, bleeding time, plasma vitamins, serum trace elements, serum autoantibody concentrations or the ability of neutrophils to kill C. albicans in healthy older subjects." The vitamin E and soybean oil placebo capsules used were provided by Roche Vitamins...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel